Global Digital Therapeutics Market Size, Share & Trends Analysis Report, By Offering (Software/Platforms, Programs, Virtual Reality/Games), By Application (Treatment/Care-Related Applications, Preventive Applications), By Revenue Model, By Sales Channel, By Region – Industry Forecast 2026-2033

The digital therapeutics market is forecasted to grow at a CAGR of 26.3% during the forecast period of 2025 - 2032.

As the prevalence of chronic disease continues to rise throughout the world, with conditions such as diabetes, cancer, and cardiovascular disease, the demand for digital therapeutics is ramping up based on the need for effective, evidence-based methods to manage and prevent chronic conditions.

The increased adoption of smart phones globally allows the widespread use of mobile health apps, cloud-based platforms and digital therapies, driving growth through the ease and personalization of health care delivery.

Digital therapeutics incorporate mobile apps, AI, machine learning, cloud-based platforms, wearables, big data analytics, and internet connectivity to provide evidence-based health care interventions and monitor outcomes.

Main treatment applications are diabetes, cardiovascular diseases, central nervous system disorders, respiratory diseases, gastrointestinal disorders, musculoskeletal disorders, medication adherence, substance use disorder, and rehabilitation therapy.

Preventive digital therapeutics are rapidly expanding in relation to obesity, prediabetes, and lifestyle applications due to increasing awareness of chronic diseases, increased chronic disease burden, and regulatory backing to improve early detection/prevention of disease.

AI is applied across therapeutic areas to enable personalized treatment trajectories and analyze patient health data, and improve clinical decision making, to improve the effectiveness of therapy and patient outcomes. In digital therapeutics, AI continues to facilitate real-time monitoring, diagnostics, and treatment.

B2B is generally looking to engage with providers, payers, and/or pharma for implementation and reimbursement. B2C is more focused on engaging directly with patients to create user-friendly experiences and allowing for more comfortable implementation and interests advancing self-management, accessibility. 

For the digital therapeutics market, there are subscription models, single purchase or annual license models, and outcome/value-based models that will be aligned to level of therapeutic success and patient improvement.

Cyber security challenges with in patient data privacy risks, and lack of regulations have limited the use of digital therapeutics because patients and providers are concerned about whether sensitive medical records will be safe.